The Northern New England Clinical Oncology Society seeks abstracts on hematology/oncology topics to share knowledge during the Annual Meeting. Physicians, nurses, mid-level providers, ancillary health care providers (psychologists, physical therapists, etc.), administrators, pharmacists, and post-graduate trainees (fellows, residents) are eligible to submit abstracts. Abstracts previously submitted to ASCO, ASH, etc. are acceptable. Limited funding through travel and expense grants will be available. NNECOS reserves the right to review and accept submissions.
Poster Presentation
Authors of accepted abstracts will be invited to attend the poster session on the evening of Friday October 29, 2010, offered a discounted meeting registration of $35.00, and are eligible to apply for a travel and expense grant.
Podium Presentation
Three abstracts will be selected for oral presentations on Saturday October 30, 2010. The responsible first author will have travel, registration, and lodging covered by NNECOS.
Selected Areas/Topics may include:
-
Novel Clinical Trials/Interventions
-
Nursing Care
-
Palliative Care
-
Business/Administrative issues
-
Pilot Studies
-
Best Clinical Practices
-
Patient and Survivor Issues
Abstracts Guidelines:
-
250 words or less, 10-12 point font
-
Affiliations clearly listed
-
Submitted electronically via email to nnecos@comcast.net, following the template available at www.nnecos.org (click on 2010 Call for Abstracts).
-
First authors will receive e-mail verification of receipt.
Submission Deadline: Tuesday, August 31, 2010 at 5pm
Contact Information
Your name, institution, address, telephone number, fax number, and email address. As the First Author
(presenter), you will receive all future correspondence from NNECOS.
Abstract Title
The title of your abstract in sentence case, capitalizing only the first letter of the first word of the title and any proper nouns or acronyms. Do not use proprietary drug names in the title; use generic drug names instead. Do not refer to study results or conclusions in the title; it should objectively describe the study. NNECOS reserves the right to edit abstract titles to conform to this policy.
Coauthor(s)
The name and institution of each coauthor.
Disclosure Declaration
A separate disclosure form should be filled out by the first author and by each co-authors.
PREPARING AN ABSTRACT
Please make special note of the following when preparing your abstract for submission.
- Describe the objectives and results of the research in the abstract so that the NNECOS Abstract Review Committee can evaluate the quality, originality, and completeness of the abstract.
- Abstracts will be judged solely on the basis of the data in the submitted abstract.
- Statements such as “further data will be available” are discouraged.
- Organize the abstract according to four sections, identified by the following headers (in bold): Background, Methods, Results, and Conclusions.
- Do not refer to study results or conclusions in the title of the abstract. The title should objectively describe the study.
- Do not use proprietary names alone in the title or body of the abstract. If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract.
- Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.
- Limit presentation of tables to one, no larger than 3” x 4”
RESPONSIBILITIES OF THE FIRST AUTHOR
The First Author must
· Verify that all coauthors are aware of the contents of the abstract and support its data.
· Agree, on behalf of all coauthors, to transfer copyright to NNECOS for publication in the annual meeting proceedings and on the NNECOS website.
-
Agree to deliver an oral presentation if selected (first authors may indicate desire to be considered for poster presentation only)
-
Agree to be present during the scheduled time of a Poster Session
-
Adhere to the following conflict of interest policy
CONFLICT OF INTEREST POLICY
NNECOS must ensure fair balance, independence, objectivity, and scientific rigor in all of its educational activities through appropriate disclosure of financial interests, among other things. The following interests or relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships at the time of submission.
2008 Abstract Program
Abstracts Selected for 2008 Annual Meeting
Identifying Priority Needs of Vermont Cancer Survivors Using Focus Groups
D. Cranmer, J. Olson
The prognostic role of PET scanning prior to non-myeloablative allogeneic
transplantation
C. Engman
Choosing and Implementing an Electronic Health Record
A. Ireland
Rapid Taper of Immune Suppression Following an Allo Transplant Resulting
in a CR in CLL
E. Kimtis
The Dartmouth experience in transplantation for Multiple Myeloma: Predictors of disease-free and overall survival
B. Lipe
Cancer survivors’ lifestyle behaviors and use of support programs and services
A. Litterini
Immune Mobilization with IL-2 and Growth Factors: Differential In Vivo Effects
of the NKG2D Receptor on CD8+ and CD56+ Effector Cells
K. Meehan
Building a toolkit to identify risk for hereditary nonpolyposis colorectal cancer
among individuals presenting for screening colonoscopy
D. Rabinowitz
Evaluation of transitional care summaries
A. Schaal
Insulin resistance, diabetes mellitus and its association with the risk of breast
cancer.
G. Torres-Mejía
